Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002513622 | SCV003443022 | pathogenic | Tuberous sclerosis 2 | 2022-09-27 | criteria provided, single submitter | clinical testing | This variant is also known as Intron5+1G>A. Disruption of this splice site has been observed in individual(s) with tuberous sclerosis complex (PMID: 17304050, 21811971). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 6 of the TSC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). ClinVar contains an entry for this variant (Variation ID: 49377). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. |
Tuberous sclerosis database |
RCV000042637 | SCV000066432 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation | ||
Clinical Molecular Genetics Laboratory, |
RCV000042637 | SCV000805047 | pathogenic | Tuberous sclerosis syndrome | 2017-08-07 | no assertion criteria provided | clinical testing |